Literature DB >> 9329075

Pimozide does not shift palatability: separation of anhedonia from sensorimotor suppression by taste reactivity.

S Peciña1, K C Berridge, L A Parker.   

Abstract

Several "taste reactivity" studies of dopamine and reward have concluded that pimozide suppresses the hedonic reaction patterns normally elicited by sucrose but enhances aversive reaction patterns elicited by quinine. However, other taste reactivity studies have failed to find hedonic/aversive shifts in reaction patterns after dopamine antagonists or dopamine lesions. The divergent conclusions have come from two different laboratories. To resolve the controversy regarding dopamine blockade and palatability, the present study joined the two laboratories to investigate the effect of pimozide on taste reactivity patterns elicited by sucrose and quinine. The results replicated many (but not all) of the earlier findings and identified procedural factors responsible for different outcomes. Overall, the results provide evidence for sensorimotor effects of pimozide on taste reactivity but not for a hedonic shift in palatability. Pimozide suppressed both hedonic and aversive reaction patterns in a gradual sensorimotor fashion when the eliciting taste stimulus was repeated or continued for several minutes. The general suppression typically did not alter the initial reaction to a taste but emerged only after an oral infusion of sucrose or quinine continued for several minutes or trials. Aversive reactions were never enhanced. The balance between hedonic and aversive reaction patterns was not shifted by pimozide. We conclude that pimozide produces a sensorimotor impairment of taste reactivity patterns but does not shift taste palatability toward anhedonia or aversion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9329075     DOI: 10.1016/s0091-3057(97)00044-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  40 in total

Review 1.  The neuroscience of natural rewards: relevance to addictive drugs.

Authors:  Ann E Kelley; Kent C Berridge
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

2.  Positive and negative motivation in nucleus accumbens shell: bivalent rostrocaudal gradients for GABA-elicited eating, taste "liking"/"disliking" reactions, place preference/avoidance, and fear.

Authors:  Sheila M Reynolds; Kent C Berridge
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

Review 3.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

4.  Metabotropic glutamate receptor blockade in nucleus accumbens shell shifts affective valence towards fear and disgust.

Authors:  Jocelyn M Richard; Kent C Berridge
Journal:  Eur J Neurosci       Date:  2010-12-29       Impact factor: 3.386

Review 5.  Calculating utility: preclinical evidence for cost-benefit analysis by mesolimbic dopamine.

Authors:  Paul E M Phillips; Mark E Walton; Thomas C Jhou
Journal:  Psychopharmacology (Berl)       Date:  2006-11-22       Impact factor: 4.530

Review 6.  The nucleus accumbens and Pavlovian reward learning.

Authors:  Jeremy J Day; Regina M Carelli
Journal:  Neuroscientist       Date:  2007-04       Impact factor: 7.519

Review 7.  Dissecting motivational circuitry to understand substance abuse.

Authors:  Robert A Wheeler; Regina M Carelli
Journal:  Neuropharmacology       Date:  2008-06-25       Impact factor: 5.250

Review 8.  'Liking' and 'wanting' food rewards: brain substrates and roles in eating disorders.

Authors:  Kent C Berridge
Journal:  Physiol Behav       Date:  2009-03-29

Review 9.  Dopamine and reward: the anhedonia hypothesis 30 years on.

Authors:  Roy A Wise
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 10.  The debate over dopamine's role in reward: the case for incentive salience.

Authors:  Kent C Berridge
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.